May 5, 2022 Newsby Marisa Wexler MSStudy Finds New Molecules Targeted by the Immune System
Researchers have identified four new brain proteins that are targeted by inflammatory T-cells in multiple sclerosis (MS), which could aid in the development of more specific and safer treatments for people with the condition. The study, “Identification of four novel T cell autoantigens and personal autoreactive profiles in…
May 4, 2022 Newsby Lindsey Shapiro PhDMaresin-1 Molecule Eases Inflammation, Symptoms in Mouse Model
Administering the maresin-1 molecule — a natural anti-inflammatory in the body — in a mouse model of multiple sclerosis (MS) led to lower levels of inflammation and improved neurological function, a recent study showed. Maresin-1 and other molecules in its family are called specialized pro-resolving mediators (SPMs) and are…
May 4, 2022 Columnsby Beth UllahRecovering My Self-esteem After Adapting to MS-related Incontinence
Without hesitation, I would say that my bladder and bowel issues have been the hardest symptoms to manage and overcome following my MS diagnosis. It comes down to one thing: the fear of having an accident in public.
May 4, 2022 Newsby Marisa Wexler MSCannabis ‘Highly Effective’ Against MS Symptoms, Some Users Report
More than half of Canadians with multiple sclerosis (MS) report using cannabis to help manage their symptoms, according to a new study. The study, “Medical cannabis use in Canadians with multiple sclerosis,” was published in Multiple Sclerosis and Related Disorders. Humans have used the cannabis plant for millennia,…
May 3, 2022 Newsby Marisa Wexler MSTysabri Every 6 Weeks Found as Effective as Standard 4-week Dosing
Tysabri (natalizumab) given every six weeks was found to be similarly effective as the standard four-week dosing schedule at stopping nervous system damage in people with relapsing-remitting multiple sclerosis (RRMS). That’s according to the full results of the Phase 3b NOVA clinical trial, which compared Tysabri dosing schedules…
May 3, 2022 Newsby Marta Figueiredo PhDUncertainties of MS Challenging in Scary Ways: UK Patient Survey
The uncertainties that accompany multiple sclerosis (MS) are among the biggest challenges faced by people with the disease, with two-thirds of patients in a recent survey saying “they’re scared for the future” because of such unknowns, the MS Society, which conducted the U.K. survey, reports. “We may all think the…
May 2, 2022 Columnsby Ed TobiasMS News That Caught My Eye Last Week: PoNS, MS Survey, Nerve Damage Biomarker, Tolebrutinib
PoNS Device for MS-associated Gait Problems Now Available in US One clinical trial showed that MS patients who used the portable neuromodulation stimulator (PoNS) device as part of an exercise program had greater improvements in gait than those using only the exercise program. A second trial showed that those…
May 2, 2022 Newsby Mary ChapmanMS Society Canada Raising Millions With Rappel Gear, Office Tower
In an unusual challenge, the Multiple Sclerosis Society of Canada is raising millions to promote multiple sclerosis (MS) research in that country by having supporters rappel off the roof of a downtown Toronto office building. More than 145 individuals across at least 36 teams are expected to participate in the…
May 2, 2022 Newsby Marisa Wexler MSNICE Briefing Covers Icobrain System for Automated MRI Scans
The National Institute for Health and Care Evidence (NICE) in England has issued a briefing on the use of Icometrix‘s icobrain system to assess disease activity in people with multiple sclerosis (MS) based on MRI scans. The NICE statement was in the form of a medtech innovation briefing, or…
April 29, 2022 Columnsby John ConnorThe MSer Who Lay in Bed for 2 Years and Can Now Walk Again
My column’s handle is “Fall Down, Get Up Again” because the first piece I wrote for Multiple Sclerosis News Today was titled “A Mountain to Climb with MS — in My Living Room.” That column got me this gig five years ago. It was set in 2012, mind you,…
April 29, 2022 Newsby Lindsey Shapiro PhDPoNS Device for MS-associated Gait Problems Now Available in US
The portable neuromodulation stimulator (PoNS) device, which improves walking abilities in people with multiple sclerosis (MS), is now available commercially in the U.S. for patients ages 22 and older who have a prescription from their healthcare provider. The device was approved last year by the U.S. Food…